The American Journal of Medicine
Volume 114, Issue 5 , Pages 377-382 , 1 April 2003

Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes

  • Philip S Mehler, MD

      Affiliations

    • Denver Health (PM, RE, TM), Denver, Colorado, USA
    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Philip S. Mehler, MD, c/o Denver Health, 660 Bannock Street, MC1914, Denver, Colorado, USA 80204
    • ,
  • Anne Esler, PhD

      Affiliations

    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • Colorado Prevention Center (AE, WH, RE, PM, TM), Denver, Colorado, USA
    • ,
  • Raymond O Estacio, MD

      Affiliations

    • Denver Health (PM, RE, TM), Denver, Colorado, USA
    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • ,
  • Thomas D MacKenzie, MD, MSPH

      Affiliations

    • Denver Health (PM, RE, TM), Denver, Colorado, USA
    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • ,
  • William R Hiatt, MD

      Affiliations

    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA
    • Colorado Prevention Center (AE, WH, RE, PM, TM), Denver, Colorado, USA
    • ,
  • Robert W Schrier, MD

      Affiliations

    • University of Colorado Health Sciences Center (PM, AE, RE, TM, WH, RS), Denver, Colorado, USA

Received 5 June 2002 ,Revised 1 October 2002 ,Accepted 28 October 2002.

References 

  1. Shepherd J, Cobbe SM, Ford I, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesteremia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307
  2. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  3. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1994;81:1329–1445
  4. Nieto FJ, Alonso J, Chambless LE, et al.  Population awareness and control of hypertension and hypercholesteremia. Arch Intern Med. 1995;155:677–684
  5. Steiner G. Lipid intervention trials in diabetes. Diabetes Care. 2000;23:B49–B53
  6. Mietten H, Lehto S, Salomaa V, et al.  Impact of diabetes on mortality after the first myocardial infarction: the FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998;21:69–75
  7. Haffner SM, Lehto S, Ronnemaa T, et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  8. Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158–1162
  9. Burke JP, Williams K, Gaskill SP, et al.  Rapid rise in the incidence of type 2 diabetes from 1987-1996. Results from the San Antonio Heart Study. Arch Intern Med. 1999;159:1450–1456
  10. Savage S, Johnson N, Estacio R, et al.  The ABCD trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes. Online J Curr Clin Trials. 1993;Nov. 24:104; Doc No.
  11. Estacio RO, Gifford N, Jeffers BW, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23:B54–B64
  12. McCulloch DK, Glasgow RE, Hampson SE, Wagner E. A systematic approach to diabetes management in the post-DCCT era. Diabetes Care. 1994;17:765–769
  13. Burt VL, Whelton P, Roccella EJ, et al.  Prevalence of hypertension in the US adult population: results from the third National Health And Nutrition Examination Survey 1988-1991. Hypertension. 1995;25:305–313
  14. Burt VL, Cutler JA, Higgins , et al.  Trends in the prevalence, awareness, treatment, and control of hypertension in the adult U.S. population. Data from the health examination surveys, 1960 to 1991. Hypertension. 1995;26:60–69
  15. Berlowitz DR, Ash AS, Hickey EC, et al.  Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957–1963
  16. ISIS-2 Collaborative Group . Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349–360
  17. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction—ISIS-I. Lancet. 1986;2:57–66
  18. McCormick D, Gurwitz JH, Lessard D, et al.  Use of aspirin, beta-blockers and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?. Arch Intern Med. 1999;159:561–567
  19. Pyorala K, Pedersen TR, Kjekshus J, et al.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620
  20. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med. 2002;112:603–609
  21. Caixas A, Ordonez-Lanos J, De Leiva A, et al.  Optimization of glycemic controls by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes. 1997;46:1207–1213
  22. Weiner JP, Parente ST, Garnick DW, et al.  Variation in office-based quality. A claims-based profile of care provided to Medicare patients with diabetes. JAMA. 1995;273:1503–1508
  23. Harris MI, Eastman RC, Cowie CC, et al.  Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care. 1999;22:403–408
  24. Larme AC, Pugh JA. Attitudes of primary care providers towards diabetes: barriers to guideline implementations. Diabetes Care. 1998;21:1391–1396
  25. Avorn J, Monette AJ, Lalcour A, et al.  Persistence of use of lipid-lowering medications: a cross national study. JAMA. 1998;279:1458–1462
  26. McBridel P, Schrott HG, Plane MD, et al.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med. 1998;159:1238–1244
  27. Yarzebski J, Bujor CF, Goldberg RJ, et al.  A community-wide survey of physician practices and attitudes toward cholesterol management in patients with recent acute myocardial infarction. Arch Intern Med. 2002;162:797–804
  28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  29. Meigs JB, Singer DE, Sullivan LM, et al.  Metabolic control and prevalent cardiovascular disease in non-insulin dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med. 1997;102:38–47
  30. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet. 1993;342:1317–1322
  31. Phillips L, Branch WT, Cook CB, et al.  Clinical inertia. Ann Intern Med. 2001;135:825–834
  32. Harris DE, Reord NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol. 1998;81:929–933
  33. Larme AC, Pugh JA. Attitudes of primary care providers towards diabetes: barriers to guideline implementation. Diabetes Care. 1998;21:1391–1396
  34. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. Arch Intern Med. 1995;155:2330–2335
  35. United Kingdom Prospective Diabetes Study Group . Tight blood pressure control and risks of macrovascular disease and microvascular complications in type 2 diabetes. BMJ. 1998;317:703–713
  36. American Diabetes Association . Management of dyslipidemia in adults with diabetes. Position statement. Diabetes Care. 2002;25(suppl 1):33–49

☆ This study was funded by a grant (DK50298) from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, and Bayer, Germany.

PII: S0002-9343(02)01566-8

doi: 10.1016/S0002-9343(02)01566-8

The American Journal of Medicine
Volume 114, Issue 5 , Pages 377-382 , 1 April 2003

Article Tools

* Image Usage & Resolution